Quick Links

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


PER Pulse Recaps highlight key points presented in Cancer Summaries and Commentaries: Update from Chicago: Advances in the Treatment and Management of Breast Cancer. The first PER Pulse Recap focuses on data from the phase III PALOMA-2 trial of first-line palbociclib for hormone receptor-positive, HER2-negative, advanced breast cancer. The second PER Pulse Recap focuses on results of the MA.17R trial of 5 years of extended letrozole therapy after 5 years of aromatase inhibitor therapy for early-stage breast cancer.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Lilly.

For further information concerning Lilly grant funding visit

Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast Cancer

Release Date: July 29, 2016
Expiration Date: July 29, 2017
Media: Internet - based

Activity Overview

This activity is designed to update participants on the most clinically impactful data on breast cancer treatment, presented at the annual 2016 Chicago meeting, so they can assess and prepare to apply these findings to their clinical practices.

CME Activity Table of Contents

  • Five years of Letrozole After 5 Years of Aromatase Inhibitor Therapy for Early Stage Breast Cancer: Results from the MA.17R Trial
  • Palbociclib Plus Letrozole Versus Letrozole for Estrogen Receptor-Positive, HER2-Negative, Advanced Breast Cancer: Primary results of the Phase III PALOMA-2 Trial
  • Palbociclib Plus Fulvestrant for Patients With Metastatic Breast Cancer and ESR1 Mutations
  • Abemaciclib After Chemotherapy for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer: Results from the Phase II MONARCH 1 Trial
  • Neoadjuvant Trastuzumab Emtansine-Pertuzumab Versus Docetaxel-Carboplatin-Trastuzumab-Pertuzumab for HER2-Positive Early Breast Cancer: Pathologic complete response rates from the KRISTINE trial
  • Atezolizumab Plus Nab-Paclitaxel for Metastatic Triple-Negative Breast Cancer: Results from a Phase Ib Study
  • Docetaxel-Cyclophosphamide Versus Anthracycline/Taxane-Based Chemotherapy Regimens for High-Risk, HER2-Negative Breast Cancer: Interim joint analysis of the phase III ABC trials

Instructions For This Activity & Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, "educational content/video" will be available for your reference.
  • In order to receive a CME certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME certificate upon completion of these steps.

Target Audience

This activity is directed toward medical and surgical oncologists who treat patients with breast cancer. Fellows, nurses, nurse practitioners, physician assistants, and other healthcare professionals involved in the management of patients with breast cancer are also invited to participate.

Educational Objectives

At the conclusion of this activity, you should be better prepared to:
  • Incorporate new data on the use of systemic therapies for breast cancer (including endocrine, cytotoxic, targeted, and bone-modifying agents) into individualized treatment plans for patients, as appropriate, based on an evaluation of efficacy and safety, as well as patient characteristics and tumor subtypes
  • Assess novel strategies for individualizing therapy based on emerging clinical data
  • Evaluate emerging clinical data regarding new agents and evolving strategies for the treatment of breast cancer, and apply clinical trial data appropriately in order to optimize the outcomes of individual patients

Faculty, Staff, and Planners' Disclosures


Ruth O'Regan, MD
Chief, Division of Hematology/Oncology
Carbone Cancer Center
University of Wisconsin
Madison, WI
Disclosure: Consultant: Genentech, Pfizer, AstraZeneca

Pamela Munster, MD
Professor of Medicine (Hematology/Oncology)
Program Leader, Developmental Therapeutics Program
Director, Early Phase Clinical Trials Unit
Helen Diller Family Comprehensive Cancer Center
University of California, San Francisco
San Francisco, CA
Disclosure: Research Support: Merck, Novartis, BioMarin, Merrimack Pharmaceuticals, Calithera, Celgene; Consultant: Huya Bioscience International


The following individuals have no relevant financial relationships with commercial interests:
The staff of PER®

Disclosure Policy and Resolution of Conflicts of Interest (COI)

It is the policy of Physicians' Education Resource®, LLC, (PER®) to ensure fair balance, independence, objectivity, and scientific rigor in all of our CME activities. In accordance with ACCME guidelines, PER® requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest to participants as a part of the activity planning process. PER® has implemented mechanisms to identify and resolve all conflicts of interest prior to release of this activity.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only, and is not meant to substitute for the independent medical judgment of a physician or nurse relative to diagnostic, treatment, or management options for a specific patient's medical condition.

The opinions expressed in the content are solely those of the individual faculty members, and do not reflect those of Physicians' Education Resource®, LLC, or any of the companies that provided commercial support for this activity.

Hardware And Software Requirements

Supported Browsers
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)

Minimum System Requirements (Windows)
  • A Pentium-based PC or compatible computer
  • At least 64MB of RAM
  • Windows 95/98/NT/ME/2000/XP/Vista system software
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise
Minimum System Requirements (Mac OS)
  • A PowerPC processor-based Macintosh computer
  • At least 64MB of RAM
  • Mac OS 7.5 or later
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise

Become a Member

Forgot Password?
Calendar of Events
Filter By